Genmab — Maj 2016
-
JnJs curtain raiser til ASCO Most notably, Phase 3 data for the immunotherapy daratumumab in combination with standard therapy have been selected for inclusion in the Plenary Session on Sunday, June 5th and will be featured in the ASCO Press Program.
-
check lige lukkeauktionen i novo...
-
Tjaah, i Europa er embargo vel noget vi bruger når Rusland invaderer små forsvarsløse naboer...
-
Nu har der været en lidt debat idag omkring pharma og biotek, er her nogen som kort kan ridse forskellen op, hvornår er et selskab biotek og hvornår er det et pharma? For der er nogle der snakker om at Gen er i en transformationsperiode fra biotek til pharma.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind